Vancouver-based Forbes Medi-Tech has signed an international supply agreement with Australian firm Pan Pharmaceuticals for Reducol, a cholesterol-lowering phytosterol-based ingredient.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more


The initial supply agreement is for a minimum of three-years, and secures Sydney-based Pan Pharmaceuticals’ exclusive rights to supply Reducol in the form of a dietary supplement to the Australian market, and selected countries in Asia, the Middle East, Africa, as well as three countries in Europe.


“This agreement will give Forbes tremendous exposure in several key
international markets,” said Charles Butt, president and CEO of Forbes Medi-Tech: “Pan Pharmaceuticals has an intimate working knowledge of the cultures, regulatory systems and product preferences in these markets, which makes it an ideal partner for Forbes.”


Reducol is used in dietary supplements in the form of tablets capsules and soft-gel capsules.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Just Food Excellence Awards - Nominations Closed

Nominations are now closed for the Just Food Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Winning five categories in the 2025 Just Food Excellence Awards, Centric Software is setting the pace for digital transformation in food and FMCG. Explore how its integrated PLM and PXM suite delivers faster launches, smarter compliance and data-driven growth for complex, multi-channel product portfolios.

Discover the Impact